- Language: English
- 322 Pages
- Published: June 2014
Global Amyotrophic Lateral Sclerosis Market 2014-2018
- Published: January 2014
- Region: Global
- 46 Pages
The analysts forecast the Global Amyotrophic Lateral Sclerosis Drugs Market to grow at a CAGR of 5.39 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Amyotrophic Lateral Sclerosis Drugs Market has also been witnessing the increasing awareness of ALS drugs. However, the patent expiry of Rilutek could pose a challenge to the growth of this market.
The report, the Global Amyotrophic Lateral Sclerosis Drugs market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, EMEA and APAC regions; it also covers the Global Amyotrophic Lateral Sclerosis Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space include Covis Pharmaceutical Inc., Eisai Co. Ltd., GlaxoSmithKline plc, and Mitsubishi Tanabe Pharma Corp.
Other vendors mentioned in the report are Amorfix Life Sciences Ltd., BrainStrom Cell Therapeutics Inc., Newron Pharmaceuticals S.p.A, Neuraltus Pharmaceuticals Inc., Nutra Pharma Corp., Oxford BioMedica plc, Pharnext SAS, and Q-Therapeutics Inc.
Key questions answered in this report:
- What will the market size be in 2016/2018 and what will be the growth rate?
- What are key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by key vendors?
- What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of our analyst's time when you purchase this market report. Details provided within the report. SHOW LESS READ MORE >
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Geographical Segmentation
08. Buying Criteria
09. Rate of Incidence and Prevalence
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
16.1 Competitive Scenario
16.1.1 Key News
16.1.2 Mergers and Acquisitions
16.2 Other Prominent Vendors
16.3 Vendor Ranking 2013
17. Late Stage Pipeline Snapshot
18. Key Vendor Analysis
18.1 Covis Pharmaceutical Inc.
18.1.1 Business Overview
18.1.2 Key Information
18.1.3 SWOT Analysis
18.2 Eisai Co. Ltd.
18.2.1 Business Overview
18.2.2 Key Information
18.2.3 SWOT Analysis
18.3 GlaxoSmithKline plc
18.3.1 Business Overview
18.3.2 Business Segmentation
18.3.3 Key Information
18.3.4 SWOT Analysis
18.4 Mitsubishi Tanabe Pharma Corp.
18.4.1 Business Overview
18.4.2 Business Segmentation
18.4.3 Key Information
18.4.4 SWOT Analysis
19. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global ALS Drugs Market 2013-2018 (US$ million)
Exhibit 3: Global ALS Drugs Market by Geographical Segmentation 2013
Exhibit 4: GlaxoSmithKline plc: Business Segmentation
Exhibit 5: Mitsubishi Tanabe Pharma Corp.: Business Segmentation
Commenting on the report, an analyst from the team said: “The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as ALS awareness month. The ALS Association strives to involve and engage patients and families in the process of increasing awareness and advocating for legislative changes. Similarly, CDMRP also organizes the ALS Research Program. The global research effort through this program has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS. ”
According to the report, one of the main drivers in this market is the increase in the aging population. The number of patients suffering from ALS is increasing due to its relatively high prevalence in the elderly population.
Further, the report states that one of the main challenges is the patent expiry of Rilutek. The patent expiry of Rilutek, the only marketed drug for the treatment of ALS, will result in the loss of market exclusivity.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
- Covis Pharmaceutical Inc.
- Eisai Co. Ltd.
- GlaxoSmithKline plc
- Mitsubishi Tanabe Pharma Corp.